Search Within

Neha Mehta Shah

Formats
  1. Journal Article (14)
  2. Meeting Abstract (9)
Groups
  1. Center for Hematologic Malignancies (23)
  2. Department of Medicine (23)
  3. Hematologic Malignancies, Division of (23)
  4. Lymphoma (23)
  5. Population Sciences Research Program (20)
  6. Survivorship Research (7)

More Groups

People
  1. Steven Horwitz (20)
  2. Alison Moskowitz (13)
  3. Andrew Zelenetz (7)
  4. Paul Hamlin (7)
  5. Ahmet Dogan (6)
  6. Craig Sauter (6)

More People

Years
  1. 2022 (2)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (2)
  5. 2018 (1)
  6. 2017 (3)

More Years

Publications
  1. Blood (5)
  2. Journal of Clinical Oncology (4)
  3. Clinical Lymphoma, Myeloma and Leukemia (3)
  4. Blood Advances (2)
  5. Acta Oncologica (1)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (8)
  2. American Society of Clinical Oncology (4)
  3. Elsevier Inc. (4)
  4. American Association for Cancer Research (1)
  5. BMJ Publishing Group Ltd. (1)
  6. C M P Medica LLC * The Oncology Group (1)

More Publishers

Results (23)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Flowers, C.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Alliance A059102: A randomized phase II US intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Geyer, S. M.; Barta, S. K.; Amengual, J. E.; Dockter, T.; Wright, C.; Dinner, S.; Hsi, E. D.; Bartlett, N. L.; Horwitz, S. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • T follicular helper phenotype prendicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma
    Journal Article

    Ghione, P.; Faruque, P.; Mehta-Shah, N.; Seshan, V.; Ozkaya, N.; Bhaskar, S.; Yeung, J.; Spinner, M. A.; Lunning, M.; Inghirami, G.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
    Journal Article

    Taylor, J.; Haddadin, M.; Upadhyay, V. A.; Grussie, E.; Mehta-Shah, N.; Brunner, A. M.; Louissaintr, A. Jr; Lovitch, S. B.; Dogan, A.; Fathi, A. T.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma
    Journal Article

    Mehta-Shah, N.; Ito, K.; Bantilan, K.; Moskowitz, A. J.; Sauter, C.; Horwitz, S. M.; Schöder, H.
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Romidepsin activity in T follicular helper(TFH)-phenotype PTCL versus non TFH treated on the same clinical trials
    Meeting Abstract

    Ghione, P.; Ozkaya, N.; Faruque, P.; Mehta-Shah, N.; Lunning, M. A.; Ruan, J.; Galasso, N.; Moskowitz, A. J.; Dogan, A.; Horwitz, S. M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Uncommon variants of T-cell lymphomas
    Journal Article

    Mehta-Shah, N.; Horwitz, S.
    Hematology/Oncology Clinics of North America (2017)

    Fulltext@MSK | Save
  • The genetic basis of hepatosplenic T-cell lymphoma
    Journal Article

    McKinney, M.; Moffitt, A. B.; Gaulard, P.; Travert, M.; Leval, L. D.; Raffeld, A. N. M.; Jaffe, E. S.; Pittaluga, S.; Xi, L.; Heavican, T.; more...
    Cancer Discovery (2017)

    Fulltext@MSK | Save